Cornell spinout Lexeo Therapeutics has added $100m to its coffers thanks to a series B round co-led by D1 Capital Partners and Eventide Asset Management.

Lexeo Therapeutics, a US-based gene therapy developer spun out of Cornell University, has raised $100m in a series B round co-led by asset managers D1 Capital Partners and Eventide Asset Management. The round included life sciences real estate investment trust Alexandria Real Estate Equities’ investment arm Alexandria Venture Investments and Lundbeckfonden Ventures, an evergreen fund…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.